Yokota, Tomoya http://orcid.org/0000-0001-7327-7949
Hamauchi, Satoshi
Kawakami, Takeshi
Fushiki, Kunihiro
Article History
Received: 18 April 2024
Accepted: 22 May 2024
First Online: 29 May 2024
Declarations
:
: This study was conducted in accordance with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the Shizuoka Cancer Center (Date: January 26, 2024/No J2023-234-2023-1-3).
: The requirement for informed consent was waived owing to the retrospective nature of the study.
: Not applicable.
: Dr. Yokota serves an advisory role for Merck Biopharma, MSD and Rakuten Medical and has received lecture fees from Merck Biopharma, Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb, AstraZeneca, Chugai, MSD and Eisai. Dr. Hamauchi serves an advisory role and has received lecture fees from Ono Pharmaceutical Co. Ltd. Dr. Kawakami serves an advisory role at Daiichi Sankyo and has received lecture fees from Ono Pharmaceutical, Bristol-Myers Squibb, Eli Lilly, Daiichi Sankyo, Yakult Honsha, Taiho Pharmaceutical, Bayer, Merck Biopharma, and AstraZeneca. Dr. Fushiki has received lecture fees from Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb, and MSD.